HUE048505T2 - Kabazitaxel vegyület - Google Patents
Kabazitaxel vegyületInfo
- Publication number
- HUE048505T2 HUE048505T2 HUE13874815A HUE13874815A HUE048505T2 HU E048505 T2 HUE048505 T2 HU E048505T2 HU E13874815 A HUE13874815 A HU E13874815A HU E13874815 A HUE13874815 A HU E13874815A HU E048505 T2 HUE048505 T2 HU E048505T2
- Authority
- HU
- Hungary
- Prior art keywords
- cabazitaxel composition
- cabazitaxel
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261848172P | 2012-12-24 | 2012-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE048505T2 true HUE048505T2 (hu) | 2020-07-28 |
Family
ID=51300216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE13874815A HUE048505T2 (hu) | 2012-12-24 | 2013-12-23 | Kabazitaxel vegyület |
Country Status (16)
Country | Link |
---|---|
US (1) | US9919053B2 (hu) |
EP (1) | EP2934593B1 (hu) |
JP (1) | JP6498610B2 (hu) |
KR (1) | KR102161866B1 (hu) |
CN (1) | CN105142671B (hu) |
AU (1) | AU2013377404B2 (hu) |
BR (1) | BR112015015202B8 (hu) |
CA (1) | CA2900508C (hu) |
DK (1) | DK2934593T3 (hu) |
ES (1) | ES2771423T3 (hu) |
HU (1) | HUE048505T2 (hu) |
MX (1) | MX371067B (hu) |
PL (1) | PL2934593T3 (hu) |
PT (1) | PT2934593T (hu) |
RU (1) | RU2678772C2 (hu) |
WO (1) | WO2014122498A2 (hu) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018109731A1 (en) * | 2016-12-16 | 2018-06-21 | Orbicular Pharmaceutical Technologies Private Limited | Pharmaceutical compositions of taxane and its derivatives |
CN108066774B (zh) * | 2018-01-11 | 2023-04-18 | 比卡生物科技(广州)有限公司 | 一种注射用卡巴他赛组合物及其制备方法 |
US20210393514A1 (en) * | 2018-07-25 | 2021-12-23 | Bika Biotechnology (Guangzhou) Co., Ltd | Docetaxel composition for injection and preparation method therefor |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1443969A2 (en) * | 2001-10-18 | 2004-08-11 | Decode Genetics EHF | Non-inclusion cyclodextrin complexes |
JP2005022989A (ja) * | 2003-06-30 | 2005-01-27 | Otsuka Pharmaceut Factory Inc | 可溶化または分散化された難溶性化合物を含む組成物 |
US20050142201A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for fabrication, uses and compositions of small spherical particles of hGH prepared by controlled phase separation |
JP2007523887A (ja) * | 2003-10-31 | 2007-08-23 | ザ・ユニヴァーシティ・オブ・カンザス | スルホアルキルエーテル−アルキルエーテルシクロデキストリン誘導体 |
CN100486645C (zh) * | 2006-09-12 | 2009-05-13 | 南京师范大学 | 含有环糊精紫杉醇包合物的药物组合物及其制备方法 |
CN100411688C (zh) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
KR101502533B1 (ko) * | 2007-11-22 | 2015-03-13 | 에스케이케미칼주식회사 | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 |
US20120065255A1 (en) * | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
US20120058971A1 (en) * | 2009-11-23 | 2012-03-08 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
WO2013024495A1 (en) * | 2011-08-18 | 2013-02-21 | Dr. Reddys Laboratories Limited | Pharmaceutical formulations of cabazitaxel |
-
2013
- 2013-12-23 JP JP2015550161A patent/JP6498610B2/ja active Active
- 2013-12-23 HU HUE13874815A patent/HUE048505T2/hu unknown
- 2013-12-23 RU RU2015130495A patent/RU2678772C2/ru not_active Application Discontinuation
- 2013-12-23 PL PL13874815T patent/PL2934593T3/pl unknown
- 2013-12-23 PT PT138748157T patent/PT2934593T/pt unknown
- 2013-12-23 DK DK13874815.7T patent/DK2934593T3/da active
- 2013-12-23 WO PCT/IB2013/003255 patent/WO2014122498A2/en active Application Filing
- 2013-12-23 EP EP13874815.7A patent/EP2934593B1/en active Active
- 2013-12-23 US US14/655,214 patent/US9919053B2/en active Active
- 2013-12-23 ES ES13874815T patent/ES2771423T3/es active Active
- 2013-12-23 CA CA2900508A patent/CA2900508C/en active Active
- 2013-12-23 BR BR112015015202A patent/BR112015015202B8/pt active IP Right Grant
- 2013-12-23 AU AU2013377404A patent/AU2013377404B2/en active Active
- 2013-12-23 KR KR1020157020157A patent/KR102161866B1/ko active Active
- 2013-12-23 MX MX2015008225A patent/MX371067B/es active IP Right Grant
- 2013-12-23 CN CN201380073396.6A patent/CN105142671B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
AU2013377404A2 (en) | 2015-08-27 |
JP6498610B2 (ja) | 2019-04-10 |
DK2934593T3 (da) | 2020-02-17 |
CA2900508A1 (en) | 2014-08-14 |
AU2013377404B2 (en) | 2018-08-23 |
PL2934593T3 (pl) | 2020-05-18 |
EP2934593A4 (en) | 2016-08-10 |
US20150328321A1 (en) | 2015-11-19 |
CA2900508C (en) | 2021-04-13 |
BR112015015202B8 (pt) | 2022-02-15 |
KR102161866B1 (ko) | 2020-10-05 |
EP2934593B1 (en) | 2020-02-05 |
RU2678772C2 (ru) | 2019-02-01 |
BR112015015202B1 (pt) | 2021-12-21 |
ES2771423T3 (es) | 2020-07-06 |
EP2934593A2 (en) | 2015-10-28 |
MX2015008225A (es) | 2016-07-20 |
JP2016508138A (ja) | 2016-03-17 |
AU2013377404A1 (en) | 2015-07-30 |
US9919053B2 (en) | 2018-03-20 |
MX371067B (es) | 2020-01-15 |
CN105142671A (zh) | 2015-12-09 |
KR20150127035A (ko) | 2015-11-16 |
CN105142671B (zh) | 2018-09-14 |
WO2014122498A2 (en) | 2014-08-14 |
BR112015015202A2 (pt) | 2017-07-11 |
PT2934593T (pt) | 2020-03-09 |
WO2014122498A3 (en) | 2014-12-04 |
RU2015130495A (ru) | 2017-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2506426B (en) | Composition | |
PL2804487T3 (pl) | Kompozycja | |
ZA201500519B (en) | Composition | |
HK1207989A1 (en) | Composition | |
EP2878295A4 (en) | COMPOSITION | |
HRP20190326T1 (hr) | Pripravak | |
GB201218954D0 (en) | Composition | |
GB2498803B (en) | Composition | |
HK1199198A1 (en) | Composition | |
EP2867307A4 (en) | COMPOSITION CONTAINING SILVER | |
GB201206035D0 (en) | Composition | |
ZA201407419B (en) | Composition | |
HK1210966A1 (en) | Misprostol composition | |
HRP20190033T1 (hr) | Pripravak | |
PT2934593T (pt) | Composição de cabazitaxel | |
EP2910537A4 (en) | AGENT COMPOSITION GENERATING GAS | |
GB201218195D0 (en) | Composition | |
GB201209597D0 (en) | Composition | |
GB201208133D0 (en) | Composition | |
GB201311517D0 (en) | Composition | |
GB201219383D0 (en) | Composition | |
HK1204230A1 (en) | Composition | |
GB201223526D0 (en) | Composition | |
GB201223224D0 (en) | Composition | |
GB201221334D0 (en) | Composition |